{"id":"conventional-adjuvant-folfox","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Neutropenia"},{"rate":"40-50","effect":"Diarrhea"},{"rate":"70-80","effect":"Nausea/vomiting"},{"rate":"60-70","effect":"Peripheral neuropathy"},{"rate":"30-40","effect":"Anemia"},{"rate":"20-30","effect":"Thrombocytopenia"},{"rate":"50-60","effect":"Fatigue"},{"rate":"20-30","effect":"Mucositis"}]},"_chembl":{"chemblId":"CHEMBL4650400","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"FOLFOX works through multiple mechanisms: fluorouracil (5-FU) inhibits thymidylate synthase and is incorporated into DNA/RNA to disrupt synthesis; leucovorin enhances 5-FU activity by stabilizing its binding to thymidylate synthase; oxaliplatin forms DNA cross-links that prevent replication. This combination is particularly effective in colorectal cancer as an adjuvant (post-surgical) treatment to eliminate residual micrometastatic disease.","oneSentence":"FOLFOX is a chemotherapy regimen that combines fluorouracil, leucovorin, and oxaliplatin to inhibit DNA synthesis and induce cell death in cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:07:33.102Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Adjuvant treatment of stage III colon cancer"},{"name":"Adjuvant treatment of stage II colon cancer (high-risk features)"}]},"trialDetails":[{"nctId":"NCT01460589","phase":"PHASE3","title":"Early Commencement of Adjuvant Chemotherapy for Colon Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kyungpook National University Hospital","startDate":"2013-01-13","conditions":"Colon Cancer","enrollment":303},{"nctId":"NCT05673772","phase":"PHASE2","title":"Preoperative Sequential Short-course Radiation Therapy and FOLFOX for Locally Advanced Rectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kyungpook National University Hospital","startDate":"2020-10-23","conditions":"Rectal Cancer","enrollment":364},{"nctId":"NCT03426904","phase":"PHASE3","title":"Neoadjuvant FOLFOX Chemotherapy for Patients With Locally Advanced Colon Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kyungpook National University Hospital","startDate":"2020-10-23","conditions":"Colon Cancer","enrollment":708},{"nctId":"NCT05775146","phase":"PHASE2","title":"SBRT of Metastases Following Neo-adjuvant Treatment for Colorectal Cancer With Synchronous Liver Metastases","status":"RECRUITING","sponsor":"AHS Cancer Control Alberta","startDate":"2024-06-18","conditions":"Colorectal Cancer, Liver Metastasis Colon Cancer","enrollment":24},{"nctId":"NCT00059930","phase":"PHASE1","title":"Adjuvant Hepatic Arterial Infusion and Combination Chemotherapy in Treating Patients With Resectable Hepatic Metastases From Colorectal Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2003-01","conditions":"Colorectal Cancer, Metastatic Cancer","enrollment":38},{"nctId":"NCT01307956","phase":"PHASE2","title":"Panitumumab, Combination Chemotherapy, & Radiation Therapy in Esophageal or Gastroesophageal Junction Cancer","status":"TERMINATED","sponsor":"University of Nebraska","startDate":"2011-02-28","conditions":"Adenocarcinoma of the Gastroesophageal Junction, Esophageal Adenocarcinoma, Stage IIA Esophageal Cancer","enrollment":11},{"nctId":"NCT06043999","phase":"NA","title":"Salvage Chemotherapy Versus Total Mesorectal Resection for Local Resection Rectal Cancer Patients","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-09-01","conditions":"Chemotherapy Effect, Rectal Cancer","enrollment":392},{"nctId":"NCT01212822","phase":"PHASE2","title":"Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer","status":"COMPLETED","sponsor":"Fox Chase Cancer Center","startDate":"2011-04-27","conditions":"Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach","enrollment":20},{"nctId":"NCT00541112","phase":"PHASE2","title":"Radiation Therapy, Chemotherapy, and Cetuximab Followed by Surgery, Chemotherapy, and Cetuximab in Treating Patients With Locally Advanced or Metastatic Rectal Cancer That Can Be Removed by Surgery","status":"TERMINATED","sponsor":"UNICANCER","startDate":"2007-10-29","conditions":"Colorectal Cancer","enrollment":19},{"nctId":"NCT00438737","phase":"PHASE2","title":"Cetuximab, Leucovorin, Oxaliplatin, and Fluorouracil With or Without Bevacizumab in Treating Patients With Resectable Liver Metastases From Colorectal Cancer","status":"UNKNOWN","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2007-01","conditions":"Colorectal Cancer, Metastatic Cancer","enrollment":100},{"nctId":"NCT00006479","phase":"PHASE3","title":"Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer","status":"UNKNOWN","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2000-09","conditions":"Colorectal Cancer, Metastatic Cancer","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Conventional adjuvant FOLFOX","genericName":"Conventional adjuvant FOLFOX","companyName":"Kyungpook National University Hospital","companyId":"kyungpook-national-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"FOLFOX is a chemotherapy regimen that combines fluorouracil, leucovorin, and oxaliplatin to inhibit DNA synthesis and induce cell death in cancer cells. Used for Adjuvant treatment of stage III colon cancer, Adjuvant treatment of stage II colon cancer (high-risk features).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}